Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

作者：Santiago Ponce Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura S. Bonanno, Egbert Frederik Smit, Alberto Chiappori, Maria Eugenia Olmedo, Ildikó Horváth, Christian Grohé, Anna F. Farago, José Antonio López-Vilariño, Martín Cullell-Young, Antonio Nieto, Noelia Vasco, Javier Gómez, Carmen Maria Kahatt, Ali Hassan Zeaiter, Enric Carcereny, Jaromı́r Roubec, Konstantinos Syrigos, Gregory K. Lo, I. Barneto, Anthony Pope, Amparo Martínez Sánchez, Joseph Gergi Kattan, Paul Zarogoulidis, Cornelius Florian Waller, Helge G. Bischoff, Óscar Juan, Niels Reinmuth, Manuel Dómine, Luis G Paz-Ares · 发表于：The Lancet Respiratory Medicine · 年份：2022 · DOI：10.1016/s2213-2600(22)00309-5 · 被引用次数：125 · 研究领域：Lung Cancer Research Studies、Lung Cancer Treatments and Mutations、Radiopharmaceutical Chemistry and Applications